Jacek J. Preibisz
Cornell University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jacek J. Preibisz.
The American Journal of Medicine | 1986
Müller Fb; Jean E. Sealey; David B. Case; Steven A. Atlas; Thomas G. Pickering; Mark S. Pecker; Jacek J. Preibisz; John H. Laragh
To develop a screening test for identifying renovascular hypertension, the blood pressure and plasma renin activity responses to an oral test dose of captopril were studied in 246 quietly seated hypertensive patients. The following criteria were developed that exploit the hyperresponsiveness of renin secretion in renovascular hypertensive patients: a 60-minute post-captopril plasma renin activity of 12 ng/ml per hour or more and an absolute plasma renin activity increase of 10 ng/ml per hour or more, along with a 150 percent increase in plasma renin activity (or a 400 percent increase if the baseline plasma renin activity was below 3 ng/ml per hour). Retrospectively, the test identified, among 200 hypertensive patients without evidence of renal dysfunction, all 56 patients with proved renovascular disease. In this group, false-positive results occurred only in two of 112 patients with essential hypertension and in six with secondary hypertension. Nine untreated patients had blood pressure levels of less than 160/100 mm Hg. The test was neither as sensitive nor specific in the 46 patients with renal insufficiency. This study demonstrates that the renin response to oral captopril is a useful screening test for identifying patients with unilateral or bilateral renovascular disease. Since the test also characterizes the renin dependency of the hypertension, it may have other diagnostic and therapeutic uses.
Journal of Clinical Oncology | 1986
George J. Bosl; Stuart P. Leitner; Steven A. Atlas; Jean E. Sealey; Jacek J. Preibisz; Ellen Scheiner
Twenty-four normotensive males in complete remission (CR) for 9+ to 54+ months after cisplatin-based chemotherapy for metastatic germ-cell tumors were evaluated for evidence of alterations in the renin-aldosterone axis and renal function. Abnormally high ambulatory plasma renin activity was seen in 14 of 19 patients with 24-hour urine sodium excretion greater than 50 mEq. This was correlated with elevated ambulatory plasma aldosterone (P = .009) and 24-hour urinary aldosterone excretion (P = .01). The mean serum magnesium value (1.34 +/- .05 mEq/L) was subnormal. Therapy resulted in an increase in serum creatinine during treatment (P less than .0001), an increase in BUN (P less than .01), and decrease in serum phosphorus (P less than .001). The relationship between the alterations in the renin-aldosterone axis and abnormal renal tubular function remains to be determined. In view of reports of cardiovascular toxicity after treatment for germ-cell tumors, and evidence individually linking both magnesium deficiency and increased plasma renin activity (PRA) to cardiovascular consequences, these abnormalities in renin and magnesium metabolism suggest that patients treated with cisplatin-based chemotherapy should be carefully observed for the development of delayed cardiovascular toxicities.
Journal of Cardiac Failure | 2009
Phyllis G. Supino; Jeffrey S. Borer; Joseph A. Franciosa; Jacek J. Preibisz; Clare Hochreiter; O.W. Isom; Karl H. Krieger; Leonard N. Girardi; Dany Bouraad; Lindsey Forur
BACKGROUND Health-related quality of life (HQOL) enhancement is a major objective of valvular surgery (VS), but assessments have been limited primarily to generic measures that may not be optimally responsive to intervention. Disease-specific instruments have been used in heart failure (HF), commonly associated with valve disease, but have been neither validated nor routinely applied among patients undergoing VS. METHODS AND RESULTS We administered the Minnesota Living with Heart Failure (MLHFQ) and SF-36 questionnaires preoperatively (T(0)) to 50 patients undergoing VS and at 1 (T(1)) and 6 months (T(2)) after VS. Performance of MLHFQ was evaluated and compared with SF-36. MLHFQ completion rates were >98% (NS vs. SF-36); Cronbachs alpha was > or = 0.9 (total score, dimensions), supporting internal reliability. Confirmatory factor analysis verified good model fit for physical/emotional domain items (relative chi-squares < 3.0, critical ratios > 2.0, both instruments), supporting structural validity. Spearman coefficients correlating MLHFQ with parallel SF-36 domains were moderate to high (0.6-0.9; P < or = .001: T(0)-T(2)), supporting convergent validity. Baseline HQOL was poorest in patients with HF (P < or = .05 [both instruments]), supporting criterion validity. Responsiveness (proportional HQOL change scores: T(0) vs. T(2)) to VS was greater with MLHFQ vs. SF-36 (P < or = .002). CONCLUSIONS Among patients undergoing VS, the MLHFQ is highly acceptable and maintains good psychometric properties, comparing favorably with SF-36. These findings suggest its utility for measuring disease-specific HQOL changes after VS.
Clinical Pharmacology & Therapeutics | 1986
Robert J. Cody; Spencer H. Kubo; Andrew B. Covit; Müller Fb; Howard Rutman; Daniel Leonard; John H. Laragh; Joseph Feldschuh; Jacek J. Preibisz
We measured systemic hemodynamics, regional blood flow, and neurohormonal parameters in 13 patients with severe chronic congestive heart failure before and after 1 month of therapy with oral milrinone, a bipyridine cardiotonic agent. After milrinone there were significant reductions in pulmonary wedge pressure (27 ± 2 to 19 ± 3 mm Hg; P < 0.02) and systemic vascular resistance (1866 ± 152 to 1393 ± 93 dyne · sec/cm5; P < 0.05) that were associated with increases in cardiac index (1.85 ± 0.15 to 2.47 ± 0.20 L/min/m2; P < 0.02). There was a marked improvement in forearm blood flow (1.98 ± 0.14 to 3.02 ± 0.16 ml/min/dl; P < 0.01) and a reduction in forearm vascular resistance (45 ± 3 to 30 ± 3 U; P<0.01). Overall there was no significant change in renal blow flow, renal vascular resistance, or glomerular filtration rate. However, there was a heterogeneous response of renal blood flow and glomerular filtration rate, such that both were directly correlated with the magnitude of increase of cardiac index (r = 0.587 [P < 0.05] and r = 0.721 [P < 0.01], respectively). After milrinone there were no significant overall or subgroup changes in urinary sodium excretion, blood volume, plasma renin activity, urinary aldosterone levels, plasma or platelet vasopressin levels, or plasma norepinephrine levels. Thus 1 month of therapy with milrinone improves systemic and forearm hemodynamics, but its effects on renal blood flow and function were heterogeneous. These heterogeneous effects on regional blood flow may depend on the relative vasodilator and inotropic effects of milrinone.
Journal of the American College of Cardiology | 2004
Phyllis G. Supino; Jeffrey S. Borer; Jacek J. Preibisz; Clare Hochreiter; Karlheinz Schuleri; Richard B. Devereux; Mary J. Roman; Paul Kligfield; Amanda D Konstam
excluded. Results: We identified 114 patients (Mean age 59+/-15yrs; 79% male), 39 (34.2%) had isolated aortic cusp prolapse and 73 (64%) had restricted cusp motion as the primary mechanism of AR. Valve repair was performed in 26 (22.8%).Two of these patients had failed repairs requiring valve replacement. Repair was more likely in younger patients, those with leaflet prolapse, tless leaflet edge thickening and less commissural calcification. By multivariate analysis, eccentric AR jet direction and less leaflet edge thickening (</= 3mm), emerged as independent determinants of likelihood of successful valve repair Conclusions: A number of echo features predict valve reparability in patients with trileaflet aortic valves, intrinsic valve pathology and primary isolated AR, with eccentric regurgitant jet direction and less leaflet edge thickness being the most important.
Heart Failure Clinics | 2006
Phyllis G. Supino; Jeffrey S. Borer; Jacek J. Preibisz; Abraham Bornstein
American Journal of Cardiology | 2007
Phyllis G. Supino; Jeffrey S. Borer; Karlheinz Schuleri; Anuj Gupta; Clare Hochreiter; Paul Kligfield; Edmund M. Herrold; Jacek J. Preibisz
American Journal of Cardiology | 2005
Phyllis G. Supino; Jeffrey S. Borer; Edmund M. Herrold; Clare Hochreiter; Jacek J. Preibisz; Karlheinz Schuleri; Mary J. Roman; Paul Kligfield
Journal of the American College of Cardiology | 2011
Phyllis G. Supino; Jeffrey S. Borer; Jacek J. Preibisz; Joseph A. Franciosa; O. Wayne Isom; Karl H. Krieger; Leonard N. Girardi; Edmund M. Herrold
Journal of the American College of Cardiology | 2011
Phyllis G. Supino; Jeffrey S. Borer; Jacek J. Preibisz; Edmund M. Herrold